← Leaderboards
Ahmed Samatar
Kalyra Pharmaceuticals, Inc.
$1,146,911
Attributed
$2,293,822
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2016–19$2M$1.5M$1M$500K$0
'16
'17
'18
'19
Funding mix
By agency
NIH$2,293,822 · 1
By mechanism
R44$2,293,822 · 1
Top collaborators
- Peter Qinhua Huang3 shared
- Deborah Slee1 shared
Most similar at Kalyra Pharmaceuticals, Inc.
Same institution · by research overlap
- Peter Qinhua Huang$998,134
Others in their field
Top investigators on “In Vivo Model”
- David Heimbrook · Leidos Biomedical Research, Inc.$345,981,914
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$216,575,541
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Richard C Boucher · University Of North Carolina Chapel Hill$76,063,312
- Leonard Freedmand · Leidos Biomedical Research, Inc.$66,248,714
Research focus
In Vivo ModelMap Kinase GeneIncidenceIn VivoMalignant Neoplasm Of PancreasMap Kinase ActivatorExtracellularHandInhibitor/AntagonistIn VitroLeadCessation Of LifeMalignant NeoplasmsMapk3 GeneClinical TrialsBinding ProteinsDiagnosisCancer Cell LineDrug CandidateBioavailableEffective TherapyInterestKras2 GeneMeks
Grant awards (4)
Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma$856,578
R44 · FY2019 · CA
Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma$1,060,799
R44 · FY2018 · CA
Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma$78,890
R44 · FY2018 · CA
Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma$297,555
R44 · FY2016 · CA